Financing - March 22, 2019
Cantargia makes directed share issue of approximately SEK 106 million
The proceeds from the share issue enable expanded investments in the company’s main project, CAN04 (nidanilimab), with a new clinical study in the US and an expansion of the most promising patient sub group of the ongoing clinical CANFOUR study. The investors are a number of Nordic institutional investors; Alecta (approximately SEK 76.5 million), Handelsbanken […]
Clinical Trials - October 16, 2017
First patient treated in Cantargia’s CANFOUR trial
The first patient in the CANFOUR clinical trial has received three cycles of treatment with the antibody CAN04 and thereby, the first patient has formally completed the safety evaluation period according to the clinical protocol. Two additional patients have received therapy with CAN04. No serious adverse events have been recorded. The ongoing clinical trial is […]
Intellectual Property - October 9, 2017
US patent approval for Cantargia
Cantargia announces that the United States Patent and Trademark Office has granted the company’s patent application directed to the product candidate CAN04. The antibody CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the intention to grant that USPTO issued in June 2017. The patent gives […]
Business article - October 6, 2017
Business in focus: Cantargia
Swedish biotech company Cantargia recently presented its 2017 Q2 results and it looks like they are ready for their next step, taking them from preclinical to clinical stage. One of the company’s most recent achievements, after the end of Q2, was the patient recruitment to its CANFOUR study. The phase I/II study has gained approval […]
Biotech Business - September 1, 2017
New patent approval for Cantargia
Cantargia announces that the European Patent Office has granted the company’s patent application on the product candidate CAN04. CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the intention to grant that EPO issued in April 2017. The patent application with number 15714603.6 which was granted […]
Clinical Trials - August 3, 2017
Cantargia gains approval to initiate clinical trial
Cantargia’s clinical trial application to study the antibody CAN04 in patients with cancer has been approved by the regulatory authorities as well as the ethics committees in Denmark and Norway. The review is ongoing in additional countries. The regulatory approvals by the Danish Medicines Agency, Norwegian Medicines Agency and by the ethics committees in Copenhagen and Oslo, follows the previously communicated […]
